Combined Amino Acid Positron Emission Tomography and Advanced Magnetic Resonance Imaging in Glioma Patients.
Philipp LohmannJan-Michael WernerN Jon ShahGereon R FinkKarl-Josef LangenNorbert GalldiksPublished in: Cancers (2019)
Imaging techniques such as positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable information about brain tumor patients. Particularly amino acid PET, advanced MRI techniques, and combinations thereof are of great interest for the non-invasive assessment of biological characteristics in patients with primary or secondary brain cancer. A methodological innovation that potentially advances research in patients with brain tumors is the increasing availability of hybrid PET/MRI systems, which enables the simultaneous acquisition of both imaging modalities. Furthermore, the advent of ultra-high field MRI scanners operating at magnetic field strengths of 7 T or more will allow further development of metabolic MR imaging at higher resolution. This review focuses on the combination of amino acid PET with MR spectroscopic imaging, perfusion- and diffusion-weighted imaging, as well as chemical exchange saturation transfer in patients with high-grade gliomas, especially glioblastomas.
Keyphrases
- positron emission tomography
- contrast enhanced
- computed tomography
- magnetic resonance imaging
- diffusion weighted imaging
- amino acid
- pet ct
- end stage renal disease
- high grade
- pet imaging
- high resolution
- magnetic resonance
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- low grade
- multiple sclerosis
- patient reported outcomes
- health information
- papillary thyroid
- blood brain barrier
- functional connectivity